

Special Issue

Cardiovascular Disease and COVID-19

Message from the Guest Editor

Cardiovascular disease is frequently found in patients with COVID-19. Arrhythmias, myocarditis, worsening heart failure, pulmonary embolism, cerebrovascular accidents, and peripheral vascular disease can affect patients infected with SARS-COV-2 virus. In addition, cardiovascular disease has also been, although very rarely, associated with vaccination against this disease. Furthermore, the potential for cardiovascular involvement in long-COVID-19 is a real threat. Consequently, studies on the subjects raised above focusing on the immunological aspects of the disease are welcome. This Special Issue aims to provide knowledge to doctors at the frontline on the SARS-COV-2-induced cardiovascular disease. Therefore, I am pleased to invite you to take part in this challenging task. For this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following: epidemiological, pathologic, clinical manifestations, subsidiary exam, clinical course, and treatment of SARS-CoV-2-induced cardiovascular disease. I look forward to receiving your contributions.

Guest Editor

Dr. Reinaldo Bulgarelli Bestetti

Department of Medicine, University of Ribeirao Preto, Ribeirao Preto, Brazil

Deadline for manuscript submissions

closed (31 August 2023)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/125762

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College
Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).